Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

NCT02674061 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

376

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC